GRAIL, Inc. research snapshot
GRAL AI stock analysis currently reads GRAIL as a high-risk, high-reward commercial-stage diagnostics company focused on multi-cancer early detection (MCED) testing. At the July 12, 2026 data cutoff, GRAL traded near $66.20 with a verified market capitalization near $2.77 billion. The company has $823 million cash, no debt, and revenue of roughly $156 million but remains pre-profit with a negative earnings trend. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$66.20
Market cap
$2.77 billion
AI score
42 / 100
Rating
High-risk pre-profit MCED diagnostics, BCBS coverage and Galleri data key
Trend status
Recovered from ASCO 2026 selloff, Samsung investment added catalyst support near $66
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | GRAIL sells the Galleri multi-cancer early detection blood test targeting asymptomatic individuals over 50. Customers pay because early cancer detection can reduce late-stage diagnoses and improve outcomes, but the test is not yet a standard-of-care covered by all insurers. | Medium |
| Moat | GRAIL has a first-mover position in MCED with the NHS-Galleri and PATHFINDER 2 datasets, IP around methylation-based detection, and commercial infrastructure. But Guardant, Natera, Exact Sciences, and other competitors are developing alternatives, limiting moat durability. | Low-medium |
| Management | Management has executed the Galleri commercial rollout, built relationships with health systems and employers, and secured strategic investment from Samsung. Key decisions include trial design choices, pricing strategy, and capital allocation between R&D and commercialization. | Medium |
| Financial trend | Revenue is growing from a small base near $156 million TTM, but the company remains deeply unprofitable with a net loss near $395 million and negative free cash flow near $108 million. The $823 million cash balance provides runway but is burning. | Medium-high |
| Valuation | At $66.20 and $2.77 billion market cap, GRAL trades at roughly 15.9x TTM revenue and 1.1x book value. EV of $2.00 billion reflects the large cash balance. These multiples are below high-growth MCED peers but still require significant adoption to justify. | Medium |
| Technical trend | Technical snapshots show GRAL recovering from an ASCO 2026 selloff with support near $50 and recent bounce to $66. The stock has a beta of 3.16, making it extremely sensitive to market moves and news flow. | Medium |
| Risk level | Main risks include pre-profit cash burn, reimbursement delays, competitive MCED tests, mixed clinical data headlines, Illumina overhang from the spinoff, key-person dependence, regulatory changes, and the need for future capital raises. | Medium-high |
| AI confidence | Medium-high for descriptive facts and audited calculations, low for forward scenarios and adoption curve estimates. | Medium-high data confidence |
| Investment certainty | Low certainty. The page frames scenarios and monitoring rules, not a buy or sell instruction. | Low |
GRAL AI stock forecast
The GRAL AI stock forecast uses scenario math around the $66.20 quote. GRAL is pre-profit and burns cash, so the forecast focuses on revenue growth, cash runway, and potential valuation scenarios rather than EPS-based models. The framework points to a bearish area near $38, a base area near $72, and a bullish area near $120 before dilution effects.
$100 to $130
More likely if Medicare and major commercial insurers expand Galleri coverage, NHS-Galleri follow-up data supports guideline inclusion, Samsung partnership drives Asia-Pacific expansion, and revenue growth accelerates toward 60%+ year-over-year, narrowing the path to breakeven.
$58 to $80
More likely if GRAL grows revenue 30% to 40% annually, expands employer-direct contracts, maintains cash runway past late 2027, but faces competitive headwinds from Guardant, Natera, and Exact Sciences without major coverage expansion.
$30 to $45
More likely if BCBS or Medicare declines broad Galleri coverage, PATHFINDER 3 or NHS follow-up data disappoints, cash burn forces a dilutive capital raise, or competitive MCED tests gain clinical adoption first.
GRAL AI technical analysis
GRAL AI technical analysis reflects a high-beta, news-driven stock with wide ranges as of the July 12, 2026 data cutoff. The stock sold off sharply after ASCO 2026 data but found support near $50 and has bounced back toward $66. The 52-week range from $29.95 to $118.84 highlights the extreme volatility, with beta at 3.16 amplifying broader market moves.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $66.20 | Quote snapshots around the July 12, 2026 cutoff placed GRAL near $66, recovering from the post-ASCO selloff. |
| Near support | $58 to $62 | Post-ASCO recovery lows near $58 to $62 provided initial support before the Samsung investment catalyst lifted the stock. |
| Key support | $50 area | The ASCO 2026 selloff bottomed near $50, making this the critical floor to watch on negative news. |
| Near resistance | $68 to $75 | Short-term resistance sits near $68 to $75, the pre-ASCO range and the initial post-spinoff trading zone. |
| Major resistance | $100+ | The 52-week high near $118.84 marks the major upside reference, requiring significant positive catalysts to challenge. |
| Momentum | High beta, news-driven | RSI and momentum indicators are less reliable for GRAL because the stock moves primarily on clinical data, reimbursement, and partnership news rather than technical patterns. |
| Volume | Average volume near 753,000 shares | Volume spikes significantly on earnings, ASCO data, and coverage announcements, making breakout quality more interpretable on volume surges. |
| Volatility | Beta 3.16, wide 52-week range | The 52-week range spans $29.95 to $118.84, meaning moves of 20% to 30% on single catalysts are normal. |
| Invalidation | Close below $50 | A decisive close below $50 would weaken the recovery thesis and suggest the ASCO disappointment is not fully priced. |
GRAL AI trading strategy
The GRAL AI trading strategy is a rules-based research framework for monitoring a pre-profit MCED diagnostics stock after mixed clinical data. It is not personal advice and should be paired with fresh trial data, coverage decisions, cash runway updates, and a defined invalidation level. The high beta means position size should reflect extreme gap risk.
Watch for GRAL to hold above $60 after positive reimbursement, partnership, or clinical follow-up news. A volume-confirmed breakout above $75 would signal renewed institutional interest. The Samsung $110M investment at $66 provides a reference anchor.
Use a stop near $50 or below the reaction low following a catalyst. Do not add to a losing position after negative coverage or trial data without fresh fundamental analysis.
If GRAL pulls back toward $55 to $60 without negative cash-burn or competitive news, compare with cash runway and revenue growth trajectory before assuming support is durable.
Do not average down without a pre-defined loss rule because MCED diagnostics stocks can gap 20%+ on Medicare coverage decisions or competitive trial readouts.
Track Galleri test volume growth, Medicare and BCBS coverage decisions, cash burn rate and runway, ASCO and other clinical data readouts, competitive MCED trial progress, Samsung partnership development, and management commentary on payer adoption.
Reduce or exit if cash runway drops below 12 months without a clear financing path, or if a major payer issues a blanket non-coverage decision for MCED testing.
Investment research summary
GRAIL sells a single blood test, Galleri, that screens for multiple cancers at once. Customers and health systems pay because finding cancer earlier can reduce late-stage treatment costs and improve survival odds, but the test is an out-of-pocket or employer-sponsored service for most, not yet standard insurance coverage.
GRAILs moat rests on the Galleri clinical dataset, the NHS-Galleri trial, an installed base of ordering physicians, and methylation-based IP. But Guardant, Natera, Exact Sciences, and others are racing to develop competing MCED tests with different technology approaches, making the moat contestable.
The thesis fails if Medicare and BCBS decline broad coverage, leaving Galleri a niche employer-pay product. It also fails if cash burn forces dilutive financing before revenue reaches scale, or if a competitor shows better sensitivity and specificity in a head-to-head comparison.
Management should be judged by commercial execution, payer contracting progress, clinical trial strategy, capital allocation between marketing spend and R&D, and whether they reach a clear path to breakeven before exhausting the $823 million cash balance.
Multi-cancer early detection sits inside a long-term structural trend toward liquid biopsy and preventive medicine. The MCED market could reach $10B+ if broad coverage materializes, but the adoption curve depends on guideline inclusion, payer reimbursement, and clinical utility evidence generation.
At roughly 15.9x TTM revenue and an enterprise value of $2.0 billion, GRAL is priced for meaningful commercial success but not for category leadership. Margin of safety is low because the company is pre-profit, the competitive timeline is uncertain, and a single negative coverage decision could halve the stock.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GRAL price | $66.20 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $2.77 billion, verified as $66.20 x approx. 41.8 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| TTM revenue | $156.12 million | Yahoo Finance key statistics | July 12, 2026 |
| TTM net income | -$395.32 million | Yahoo Finance key statistics | July 12, 2026 |
| Cash and investments | $823.11 million | Yahoo Finance key statistics | July 12, 2026 |
| Enterprise value | $2.00 billion | Yahoo Finance key statistics | July 12, 2026 |
| Levered free cash flow | -$107.75 million (TTM) | Yahoo Finance key statistics | July 12, 2026 |
| Samsung equity investment | $110 million at roughly $66 per share | PR Newswire via Yahoo Finance | July 12, 2026 |
| Key valuation ratios | Price/Sales 15.86, Price/Book 1.11, EV/Revenue 12.81 | Yahoo Finance key statistics | July 12, 2026 |
| Beta | 3.16 | Yahoo Finance key statistics | July 12, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell GRAL stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. GRAIL is a pre-profit commercial-stage company with significant cash burn, competitive, and reimbursement risks. Always verify current filings, prices, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
